Premature aging/senescence in cancer cells facing therapy: good or bad?

Biogerontology
Llilians Calvo GonzalezFrancis Rodier

Abstract

Normal and cancer cells facing their demise following exposure to radio-chemotherapy can actively participate in choosing their subsequent fate. These programmed cell fate decisions include true cell death (apoptosis-necroptosis) and therapy-induced cellular senescence (TIS), a permanent "proliferative arrest" commonly portrayed as premature cellular aging. Despite a permanent loss of proliferative potential, senescent cells remain viable and are highly bioactive at the microenvironment level, resulting in a prolonged impact on tissue architecture and functions. Cellular senescence is primarily documented as a tumor suppression mechanism that prevents cellular transformation. In the context of normal tissues, cellular senescence also plays important roles in tissue repair, but contributes to age-associated tissue dysfunction when senescent cells accumulate. Theoretically, in multi-step cancer progression models, cancer cells have already bypassed cellular senescence during their immortalization step (see hallmarks of cancer). It is then perhaps surprising to find that cancer cells often retain the ability to undergo TIS, or premature aging. This occurs because cellular senescence results from multiple signalling pathways, some ...Continue Reading

References

May 31, 1990·Nature·C B HarleyC W Greider
Dec 1, 1995·The Journal of Biological Chemistry·A C Newton
Sep 26, 1995·Proceedings of the National Academy of Sciences of the United States of America·G P DimriO Pereira-Smith
May 9, 1995·Proceedings of the National Academy of Sciences of the United States of America·Q ChenB N Ames
May 10, 1994·Proceedings of the National Academy of Sciences of the United States of America·Q Chen, B N Ames
Jul 1, 1993·Physiological Reviews·V J Cristofalo, R J Pignolo
Apr 1, 1993·Trends in Genetics : TIG·B Vogelstein, K W Kinzler
Apr 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·T M Bryan, R R Reddel
Sep 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·E A HarringtonN Dyson
May 25, 1999·Cell·J D GriffithT de Lange
Oct 6, 1999·Current Biology : CB·D N SheltonW D Funk
Sep 27, 2000·Proceedings of the National Academy of Sciences of the United States of America·E C GoodwinE S Hwang
Feb 7, 2001·Arteriosclerosis, Thrombosis, and Vascular Biology·M FentonJ D Erusalimsky
Feb 7, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·E VasileH F Dvorak
Apr 20, 2001·Proceedings of the National Academy of Sciences of the United States of America·M GstaigerW Krek
Jan 10, 2002·Nature·Stuart D TynerLawrence A Donehower
Mar 6, 2002·The Journal of Biological Chemistry·Zhiyong HanJames H Wyche
Jun 28, 2002·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Stefanie U WiemannK Lenhard Rudolph
Jul 9, 2002·The Journal of Biological Chemistry·Lynne W ElmoreShawn E Holt
Feb 26, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Bernd SchnablDavid Brenner
Jun 5, 2003·Cancer Cell·Jiri Bartek, Jiri Lukas
Jul 12, 2003·Nature Cell Biology·Simona ParrinelloJudith Campisi
Jul 29, 2003·Aging Cell·Jo S PriceIan M Clark
Aug 13, 2003·The EMBO Journal·Christian M BeauséjourJudith Campisi
Dec 1, 1961·Experimental Cell Research·L HAYFLICK, P S MOORHEAD
Nov 11, 2003·Nature·Fabrizio d'Adda di FagagnaStephen P Jackson
Jan 15, 2004·The Journal of Clinical Investigation·Norman E Sharpless, Ronald A DePinho
Feb 12, 2004·Genes & Development·Bernhard MaierHeidi Scrable
Jul 21, 2004·Cancer Cell·Minna AllinenKornelia Polyak
Nov 3, 2004·The Journal of Clinical Investigation·Janakiraman KrishnamurthyNorman E Sharpless
Jan 5, 2005·Nature Reviews. Cancer·Bruce A Chabner, Thomas G Roberts

❮ Previous
Next ❯

Citations

Jan 14, 2016·Biogerontology·Tamas Fulop
May 29, 2016·Ageing Research Reviews·Ia PantsulaiaJolanta Niewiarowska
Apr 25, 2018·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Zehua WangCongjian Xu
Aug 14, 2020·EMBO Reports·Nicolas MalaquinFrancis Rodier
Mar 16, 2019·International Journal of Molecular Sciences·Anna Bielak-ZmijewskaEwa Sikora
Feb 14, 2019·American Journal of Respiratory Cell and Molecular Biology·Diederik E van der FeenBeatrijs Bartelds
Feb 12, 2019·Journal of Gynecologic Oncology·Zehua WangCongjian Xu
Jan 11, 2020·Frontiers in Cardiovascular Medicine·Shohreh MalekiPer Eriksson
Feb 28, 2020·Oxidative Medicine and Cellular Longevity·Yujie ZhangWenjian Ma
Jan 11, 2020·Computational and Structural Biotechnology Journal·Paula Santos-OtteStuart Maudsley
Jul 14, 2021·Aging·Céline WarnonFlorence Debacq-Chainiaux
Aug 31, 2021·Frontiers in Cell and Developmental Biology·Jing YangXing Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis